Acute Porphyria Drug Database

J07BC20 - Combinations
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the hepatitis combination vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated hepatitis A virus and hepatitis B virus surface antigen.
Therapeutic characteristics
The hepatitis combination vaccine is indicated for use in non-immune adults and children from the age of 1 year and above who are at risk of both hepatitis A and hepatitis B infection. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmacokinetics
The hepatitis vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Twinrix. (Last edition: January 2015). #1877

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BC or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙